Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

The U.S. Department of Agriculture has given a conditional approval to Zoetis to use its bird flu vaccine in poultry, the ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Moderna reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 5% in premarket ...

Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

the technology used in the Moderna and Pfizer shots, the researchers said. In clinical trials, J&J's vaccine had shown an 85% efficacy. In subsequent studies in the general population, this figure ...